Clinical Trials Logo
  1. Home
  2. Hypothalamic Obesity
  3. NCT05147415

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

Hypothalamic Obesity Clinical Trial

Official title:
A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Hypothalamic Obesity

Clinical Trial Summary

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05147415
Study type Interventional
Source Saniona
Contact
Status Withdrawn
Phase Phase 2
Start date November 11, 2021
Completion date December 9, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT02849743 - Intranasal Oxytocin in Hypothalamic Obesity Phase 2
Recruiting NCT06217848 - The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study Early Phase 1
Completed NCT00892073 - Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Phase 2
Not yet recruiting NCT06299891 - Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phase 2
Recruiting NCT06239116 - A Study of RM-718 in Healthy Subjects and in Patients With HO Phase 1
Completed NCT02664441 - Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Phase 3
Completed NCT04725240 - Open-Label Study of Setmelanotide in Hypothalamic Obesity Phase 2
Completed NCT03673813 - A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
Not yet recruiting NCT06046443 - A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Phase 2
Withdrawn NCT03708913 - Neuromodulation for Hypothalamic Obesity N/A
Completed NCT01061775 - Effects of Exenatide on Hypothalamic Obesity Phase 1/Phase 2
Completed NCT02860923 - Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Phase 3
Completed NCT00171613 - A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients Phase 4
Recruiting NCT01783717 - Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage N/A
Enrolling by invitation NCT05774756 - A Trial of Setmelanotide in Acquired Hypothalamic Obesity Phase 3
Completed NCT05319301 - Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study) N/A